A 22-year-old patient suffering from Pectus Excavatum was operated on by Dr. Fernando Cózar Bernal with the new Pectus Up extrathoracic method.
The surgery took place on September 4 at the hospital Fátima, with prior authorization by Adeslas for the use of the Pectus Up extrathoracic implant, developed by Ventura Medical Technologies. The result was highly satisfactory.
The patient remained three days in a conventional hospitalization room and was discharged with oral analgesia.
Dr. Fernando Cózar is a specialist surgeon in the Thoracic Surgery Area of the hospital Virgen Macarena in Seville (Spain) and in the Fatima Hospital, where he performed this surgery. He is a member of several medical associations, such as the Asociación Española de Cirujanos (Spanish Association of Surgeons), the Asociación Iberoamericana de Cirugía Torácica (Ibero-American Association of Thoracic Surgery), the European Society of Thoracic Surgeons and NEUMOSUR, among others.
More than 60 doctors from more than 25 specialties are attending at the Center for Medical Specialties of the Hospital Fátima. This center is committed to innovation and modern diagnostic and treatment techniques are applied to offer an excellent assistance. It is internationally certified in accordance with the ISO 9001: 2015 standard and SEP 2016 Model (Private Excellent Health).
SegurCaixa Adeslas is the leading non-life insurance company in Spain in health, with a market share of over 28% and integrated in the Grupo Mutua Madrileña and participated by CaixaBank.
Also called sunken chest, Pectus Excavatum is the most frequent congenital deformity of the thoracic cavity. It represents almost 95% of the cases and it is characterized by a concave depression of the sternum.
The Pectus Up represents an important technological innovation in the world of chest surgery for the treatment of Pectus Excavatum. It stands out for the low presence of pain and the rapid recovery of the patient.
This new surgical method is a great alternative for the treatment of Pectus Excavatum and offers great advantages to the patient, the surgeon and the National Health System or the insurance company.
It has been validated by the AEMPS (Spanish Medicines and Health Products Agency) and it is CE certified since 2015. It is marketed in different European countries (France, United Kingdom, Italy and Portugal), and also in Mexico, Colombia, Chile, Peru and Costa Rica. Currently, it is in the process of obtaining the FDA registration for its commercialization in the USA.
The product is already being used in several hospitals in these countries and in Spain, specifically in public and private hospitals in the communities of Madrid, Catalonia, La Rioja, the Balearic and Canary Islands, Castilla León, Andalusia and Valencia, with excellent results and with no recurrences.
Insurance companies like Adeslas can help many patients affected by Pectus Excavatum to benefit from the great advantages of this new, minimally-invasive method.